Anakinra versus treatment as usual in the treatment of acute gout - ATTACG

prof. dr. M.A.F.J. van de Laar0 个研究点目标入组 200 人开始时间: 2015年6月12日最近更新: 2019年11月25日

适应症

试验速览

暂无简介。

•At least 18 years of age
•Signed written informed consent
•Identification of intracellular monosodium urate crystals in primary joint through aspiration of joint
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 100
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 100

•Absolute contra-indication for urate lowering therapy
•Absolute contra-indication for anakinra
•Presence of liver disease that according to the treating physician precludes participation in the study
•Absolute contra-indication for all three possible standard of care treatments (colchicine, naproxen, prednisolon)
•Known history of allergy or sensitivity to latex
•Current use of any ULT
•Concurrent use of other IL-1 agents
•Patient reports no to mild gout related pain
•Pregnancy or lactation
•Women who are planning on becoming pregnant within the study period (12 months)
•Patients with active or recurrent bacterial, fungal or viral infection
•Patients using tumor necrosis factor inhibitors
•Patient has insufficient knowledge of the Dutch language for completing questionnaire independently

发起方

prof. dr. M.A.F.J. van de Laar